Locations:
Search IconSearch
March 23, 2017/Cancer/News & Insight

New Cancer Center Houses Ohio’s Most Advanced Gamma Knife Technology

Icon one of many upgrades in new building

suh-icon_650x450

The new Taussig Cancer Center building, which opened March 6, 2017, houses Ohio’s first Leksell Gamma Knife Icon™ radiosurgery technology. Icon offers the most precise brain radiosurgery capabilities of any currently available technology.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The addition of this new technology further enhances patient care, research and education at Cleveland Clinic Cancer Center. Since 1997, the center has performed over 6000 cases using Gamma Knife for brain tumor treatment. Cleveland Clinic is also one of the few centers to offer a week-long Gamma Knife training course, which has trained hundreds of physicians and medical physicists. In addition, the center is active in scientific and clinical research, has ongoing clinical trials for patients with brain metastases and holds an annual international symposium on radiosurgery.

Upgraded features benefit patient care

Icon’s front-mounted, cone-beam CT scanner allows the physician to verify the patient’s head position prior to treatment. This verification enables physicians to treat tumors in locations close to critical structures such as the optic apparatus and brain stem, and to replace rigid frames that screw into a patient’s skull with a mask as a stereotactic reference.

The mask “offers a better patient experience for some patients and allows us to divide treatments over multiple sessions, which is useful for some complex cases,” says John Suh, MD, Chair of the Department of Radiation Oncology at Cleveland Clinic’s Taussig Cancer Center and Associate Director of the Gamma Knife Center. The presence of high-definition motion management, which uses an infrared camera, monitors any patient motion during treatment.

Icon one of many upgrades in new building

The new 377,000-square-foot, $276 million Cancer Center building is designed, top to bottom, to “optimize multidisciplinary care and patient experience and minimize wait times,” says Dr. Suh. The light-filled building extends its brightness to the lower level of the radiation treatment center with an enormous standing skylight that protrudes into the parking drop off area. “The presence of natural light into the radiation oncology department is very important. It helps make the space more open and inviting, which helps comfort patients and their families,” says Dr. Suh.

Advertisement

All radiation treatments will occur in the new Cancer Center. Six state-of-the-art linear accelerators with image guidance, two large bore CT simulators, a hyperthermia suite, a high-dose rate brachytherapy suite and MRI for simulation will join Icon in the array of radiation treatments available for Cleveland Clinic patients. In addition, the lower level will feature a large physician conference room with two 100-inch monitors.

“It’s a very exciting time in oncology, in particular radiation oncology,” says Dr. Suh. “We plan to create the future of cancer care in the new Taussig Cancer Center by providing timely, compassionate, innovative and comprehensive cancer care.”

Advertisement

Related Articles

Dr. Angelini
December 24, 2025/Cancer/News & Insight
Study Analyzes Direct Oral Anticoagulants Use in Patients with Brain Metastases

Large retrospective study suggests DOACs are safe, effective alternative to low-molecular-weight heparin in complex patient population

Lobular breast cancer cells
December 22, 2025/Cancer/Innovations
Comprehensive Lobular Breast Cancer Program Addresses Often-Misunderstood Disease

Care paths and research initiatives aim to answer unmet clinical needs

Dr. Singh
December 19, 2025/Cancer/Blood Cancers
IDH1 Inhibitor Found Safe and Effective in Rare Precursor to Blood Malignancies

Study shows high rate of hematologic responses, low rate of disease progression

Shahzad Raza, MD
December 18, 2025/Cancer/Blood Cancers
Talquetamab Provides Lifesaving Bridge to CAR T-Cell Therapy

Bispecific antibody bridging therapy deepens durability of BCMA CAR T-cell therapy without overlapping toxicities in patients with relapsed/refractory multiple myeloma

Dr. Raza
December 16, 2025/Cancer/Blood Cancers
Dual Bispecifics May Redefine Management of Extramedullary Myeloma

Phase 2 study brings pivotal advances in treatment efficacy and safety for the most challenging-to-treat population

CAR T-cell therapy
December 15, 2025/Cancer/Blood Cancers
Case Study: Patient Remains Disease Free Five Years After Allogenic CAR T-Cell Therapy

Patient with quadruple refractory multiple myeloma achieves complete response with cell therapy

J. Joseph Melenhorst, PhD
December 12, 2025/Cancer/Blood Cancers
Researchers Identify Predictors of Response to CAR T-Cell Therapy in B-Cell Non-Hodgkin’s Lymphoma

Distinct baseline immune profiles can predict response and resistance to different types of CAR-T cells.

church bus tour
December 9, 2025/Cancer/News & Insight
Novel Community Campaign Increases Venous Thromboembolism Awareness

National Blood Clot Alliance collaborates with faith-based organizations on first-of-its-kind church bus tour

Ad